Hannah Carolan
YOU?
Author Swipe
View article: Ultrarapid EGFR Testing in Non–Small Cell Lung Carcinoma Patients: Findings From a Canadian Clinical Testing Workflow
Ultrarapid EGFR Testing in Non–Small Cell Lung Carcinoma Patients: Findings From a Canadian Clinical Testing Workflow Open
Single vs multigene molecular testing modalities for lung cancer offer distinct advantages and risks. We examined lung cancer cases with clinically requested ultrarapid EGFR testing to (1) identify clinical features of rapid tested cases a…
View article: Treatment with Stereotactic Ablative Radiotherapy for up to Five Oligometastases in Patients with Cancer: Long-Term Outcomes of the Nonrandomized Phase 2 SABR-5 Clinical Trial
Treatment with Stereotactic Ablative Radiotherapy for up to Five Oligometastases in Patients with Cancer: Long-Term Outcomes of the Nonrandomized Phase 2 SABR-5 Clinical Trial Open
View article: 7 POPULATION-BASED PATTERNS OF RADIATION THERAPY USE FOR BRAIN METASTASIS PATIENTS IN BRITISH COLUMBIA FROM 2017-2022
7 POPULATION-BASED PATTERNS OF RADIATION THERAPY USE FOR BRAIN METASTASIS PATIENTS IN BRITISH COLUMBIA FROM 2017-2022 Open
PURPOSE To characterize radiotherapy (RT) use for brain metastases (BM) in British Columbia (BC) from January 2017 to December 2022. METHODS Patients who received BM-directed RT were identified from the BC Cancer registry and RT delivery s…
View article: 16 ASSOCIATION OF LOCAL CONTROL AND RADIATION NECROSIS WITH MARGIN FOR PLANNED TARGET VOLUME FOR BRAIN METASTASIS
16 ASSOCIATION OF LOCAL CONTROL AND RADIATION NECROSIS WITH MARGIN FOR PLANNED TARGET VOLUME FOR BRAIN METASTASIS Open
PURPOSE To compare local control (LC) and radiation necrosis (RN) rates for stereotactic radiation therapy (SRT) using 0mm vs. 1mm planned target volume (PTV) margin for brain metastasis (BM). METHODS A retrospective chart review was condu…
View article: Population-Based Real-World Outcomes of Post-Operative Adjuvant Brain Cavity Radiotherapy Versus Observation
Population-Based Real-World Outcomes of Post-Operative Adjuvant Brain Cavity Radiotherapy Versus Observation Open
To evaluate the factors influencing the outcomes of patients who underwent surgical resection of brain metastasis followed by either surveillance or post-operative stereotactic radiosurgery/fractionated radiotherapy (SRS/SFRT), a retrospec…
View article: Reduced wait times for molecular-biomarker testing among patients with advanced lung cancer using parallel sample processing and closed-loop communication: the Continuous Oncopanel and ALK Status Tracking (COAST) Project
Reduced wait times for molecular-biomarker testing among patients with advanced lung cancer using parallel sample processing and closed-loop communication: the Continuous Oncopanel and ALK Status Tracking (COAST) Project Open
Background Given how crucial molecular-biomarker testing is to treatment decisions for advanced non-small cell lung cancer (NSCLC), guidelines recommend a turnaround time (TAT) of 14 calendar days from receiving specimen to test result, an…
View article: Single vs. multiple fraction non-inferiority trial of stereotactic ablative radiotherapy for the comprehensive treatment of oligo-metastases/progression: SIMPLIFY-SABR-COMET
Single vs. multiple fraction non-inferiority trial of stereotactic ablative radiotherapy for the comprehensive treatment of oligo-metastases/progression: SIMPLIFY-SABR-COMET Open
View article: RADT-16. A RETROSPECTIVE COMPARISON OF OUTCOMES AFTER WHOLE BRAIN RADIOTHERAPY AND RAPID SIMPLE (RAPPLE) TARGETED THERAPY FOR BRAIN METASTASES IN MATCHED COHORTS OF PATIENTS WITH POOR PROGNOSIS
RADT-16. A RETROSPECTIVE COMPARISON OF OUTCOMES AFTER WHOLE BRAIN RADIOTHERAPY AND RAPID SIMPLE (RAPPLE) TARGETED THERAPY FOR BRAIN METASTASES IN MATCHED COHORTS OF PATIENTS WITH POOR PROGNOSIS Open
BACKGROUND For patients whose poor prognosis does not warrant stereotactic radiosurgery, we use the RAPPLE radiotherapy technique to treat multiple brain metastases. RAPPLE uses single-isocenter, coplanar volumetric modulated arc therapy a…
View article: Stereotactic Ablative Radiotherapy for Oligo-Progressive Cancers: Results of the Randomized Phase II STOP Trial
Stereotactic Ablative Radiotherapy for Oligo-Progressive Cancers: Results of the Randomized Phase II STOP Trial Open
View article: Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer
Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer Open
Importance After the publication of the landmark SABR-COMET trial, concerns arose regarding high-grade toxic effects of treatment with stereotactic ablative body radiotherapy (SABR) for oligometastases. Objective To document toxic effects …
View article: Population Based Phase II Trial of Stereotactic Ablative Radiotherapy (SABR) for up to 5 Oligometastases: Preliminary Results of the SABR-5 Trial
Population Based Phase II Trial of Stereotactic Ablative Radiotherapy (SABR) for up to 5 Oligometastases: Preliminary Results of the SABR-5 Trial Open
View article: Radiation Oncology Resident and Program Director Perceptions of the Job Market and Impact on Well-being
Radiation Oncology Resident and Program Director Perceptions of the Job Market and Impact on Well-being Open
Background Radiation oncology graduates occasionally experience difficulties obtaining employment. The purpose of this study was to explore the perceptions of radiation oncology residents (RORs) and program directors (PDs) about the job ma…
View article: EP-1616 Population-based Phase II Trial of Stereotactic Radiotherapy for up to 5 Oligometastases: SABR-5
EP-1616 Population-based Phase II Trial of Stereotactic Radiotherapy for up to 5 Oligometastases: SABR-5 Open
View article: Re‐irradiation volumetric modulated arc therapy optimization based on cumulative biologically effective dose objectives
Re‐irradiation volumetric modulated arc therapy optimization based on cumulative biologically effective dose objectives Open
The objective of this note is to introduce a clinical tool that generates ideal base plan dose distributions to enable re‐irradiation volumetric modulated arc therapy (VMAT) optimization based on cumulative biological effective dose object…
View article: Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5
Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5 Open
View article: The Impact of a Central Nervous System Event on Cognitive Function After Volumetric Radiosurgery and Adjuvant Whole-Brain Radiation Therapy in Patients With 1 to 10 Brain Metastases
The Impact of a Central Nervous System Event on Cognitive Function After Volumetric Radiosurgery and Adjuvant Whole-Brain Radiation Therapy in Patients With 1 to 10 Brain Metastases Open
View article: 122: The Impact of a Central Nervous System Event on Cognitive Function After Radiation Treatment in Patients With One-Ten Brain Metastases
122: The Impact of a Central Nervous System Event on Cognitive Function After Radiation Treatment in Patients With One-Ten Brain Metastases Open
View article: Volumetric Radiosurgery for 1 to 10 Brain Metastases: A Multicenter, Single-Arm, Phase 2 Study
Volumetric Radiosurgery for 1 to 10 Brain Metastases: A Multicenter, Single-Arm, Phase 2 Study Open
For non-deep brain metastases, 47.5 Gy in 5 fractions was tolerable. Volumetric radiosurgery was effective for long-term control of treated brain metastases.
View article: EP-1180: VMAT makes it possible to treat more advanced stages of NSCLC compared to 3D-CRT
EP-1180: VMAT makes it possible to treat more advanced stages of NSCLC compared to 3D-CRT Open